ep risk like linger
rate underweight given high visibl below-
consensu ep weaker lt top-line growth
prospect believ market perceiv
takeaway see key increment point post eps/low
guidanc prior concern guidanc high
play ep revis view new guidanc
rang reason worri ep hangov
reinvest behind busi support top-line
growth difficult competit environ discretionari tighten
item incent compens may present profit headwind
market share pressur seem build
unround org sale result consensu two-yr
average org sale result prior five quarter
perform market weaken organ sale growth
two-yr average basi yoy two-yr average
respect result prior five quarter concern declin
china heighten competit despit diaper innov see
price power mute confirm near price result despit yoy
profit impact higher commod na person price particular
concern corpor level sound like expect
moder yoy price
number ep came cent consensu in-lin
ms downwardli revis ep guidanc cent
midpoint prior qualiti subpar
flat organ sale unround volum slight price
declin off-set bp mix result market expect
rang top-line downsid augment bp gm miss lead
gross profit downsid vs consensu gross profit downsid off-set
lower mr sg larg bp yoy cost save
reduc discretionari spend drive oper profit beat vs
consensu led ep beat
remain uw net believ revis ep guidanc rang look
achiev believ reinvest busi address market
household person unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
share pressur remain necessari especi larg bp yoy mr
cut sale averag last quarter like creat
comparison headwind remain uw lower ep
estim reflect oner commod fx partial
off-set lower tax rate price target remain unchang
unfavor risk/reward build topline/margin/ep risk
unfavor risk/reward build topline/margin/ep risk
long-term organ revenu growth
beyond lt
guidanc averag
consensu driven competit concern
pg/privat label pressur north
america profit local compani
pressur china forecast burgeon
market share loss us china
global given competit
growth declin birth rate
margin limit commod
term margin risk higher commod
inflat base detail bottom-up
commod build ms colleagu
longer term see risk need
increas spend combat burgeon
share loss difficult competit
risk achiev price
upsid risk includ lower pulp
deceler upsid cost save improv
industri price usd weaken
pt reflect base case assumpt
price pass-through weaker-than-expect commod drive margin
upsid innovation/trad privat label drive volum upsid
bp price off-set commod lower fear bp
volum upsid trade up/new product usd weaken valuat
expand ep slightli last averag
modest top-line rebound limit commod inflat pass
organ sale growth rebound oper profit margin
contract bp expand bp driven commod
cost valuat ep histor
averag ntm price-to-earnings given sluggish top-line growth margin pressur
price weaken pg/pl pressur volum share loss input cost
ramp competit pressur increas drive price bp volum
bp forecast commod cost add bp oper margin
downsid usd strengthen valuat contract ep one
standard deviat last averag
exhibit bear bull price commod cut driver
product sold
sale
sale bp chang
sale
sale bp chang
incom equiti interest
net incom equiti compani
net incom non-controlling interest
